Literature DB >> 12848473

Managing complicated urinary tract infections: the urologic view.

Jonathan N Rubenstein1, Anthony J Schaeffer.   

Abstract

Patients with complicated UTIs are a diverse group. These patients have upper UTIs and structural or functional abnormalities that reduce the efficacy of antimicrobial therapy. They are at increased risk for morbidity such as bacteremia and sepsis, perinephric abscess, renal deterioration, and emphysematous pyelonephritis. Appropriate urinary tract imaging, antimicrobials, medical and surgical therapies, and follow-up are required to avoid potentially devastating outcomes.

Entities:  

Mesh:

Year:  2003        PMID: 12848473     DOI: 10.1016/s0891-5520(03)00012-6

Source DB:  PubMed          Journal:  Infect Dis Clin North Am        ISSN: 0891-5520            Impact factor:   5.982


  10 in total

1.  Is single-dose fosfomycin trometamol a good alternative for asymptomatic bacteriuria in the second trimesterof pregnancy?

Authors:  Omer Bayrak; Ersin Cimentepe; Ilknur Inegöl; Ali Fuat Atmaca; Candan Iltemir Duvan; Akif Koç; Nilgün Oztürk Turhan
Journal:  Int Urogynecol J Pelvic Floor Dysfunct       Date:  2006-08-29

2.  Adequacy of an evidence-based treatment guideline for complicated urinary tract infections in the Netherlands and the effectiveness of guideline adherence.

Authors:  V Spoorenberg; J M Prins; E E Stobberingh; M E J L Hulscher; S E Geerlings
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2013-07-04       Impact factor: 3.267

Review 3.  Spontaneous perirenal hemorrhage: what radiologists need to know.

Authors:  Jesus R Diaz; Demetrios J Agriantonis; Jorge Aguila; Jesus E Calleros; Anoop P Ayyappan
Journal:  Emerg Radiol       Date:  2011-02-23

4.  Clinico-microbiological profile of urinary tract infection in south India.

Authors:  M Eshwarappa; R Dosegowda; I Vrithmani Aprameya; M W Khan; P Shiva Kumar; P Kempegowda
Journal:  Indian J Nephrol       Date:  2011-01

5.  Treatment duration of febrile urinary tract infections.

Authors:  Willize E van der Starre; Jaap T van Dissel; Cees van Nieuwkoop
Journal:  Curr Infect Dis Rep       Date:  2011-12       Impact factor: 3.725

6.  Cumulative clinical experience from over a decade of use of levofloxacin in urinary tract infections: critical appraisal and role in therapy.

Authors:  Larry M Bush; Fredy Chaparro-Rojas; Victor Okeh; Joseph Etienne
Journal:  Infect Drug Resist       Date:  2011-10-18       Impact factor: 4.003

7.  Treatment duration of febrile urinary tract infection (FUTIRST trial): a randomized placebo-controlled multicenter trial comparing short (7 days) antibiotic treatment with conventional treatment (14 days).

Authors:  Cees van Nieuwkoop; Jan W van't Wout; Willem J J Assendelft; Henk W Elzevier; Eliane M S Leyten; Ted Koster; G Hanke Wattel-Louis; Nathalie M Delfos; Hans C Ablij; Ed J Kuijper; Jan Pander; Jeanet W Blom; Ida C Spelt; Jaap T van Dissel
Journal:  BMC Infect Dis       Date:  2009-08-19       Impact factor: 3.090

8.  Differences in the pattern of antibiotic prescription profile and recurrence rate for possible urinary tract infections in women with and without diabetes.

Authors:  Caroline Schneeberger; Ronald P Stolk; J Hans Devries; Peter M Schneeberger; Ron M Herings; Suzanne E Geerlings
Journal:  Diabetes Care       Date:  2008-03-24       Impact factor: 19.112

9.  Appropriate antibiotic use for patients with complicated urinary tract infections in 38 Dutch Hospital Departments: a retrospective study of variation and determinants.

Authors:  V Spoorenberg; S E Geerlings; R B Geskus; T M de Reijke; J M Prins; M E J L Hulscher
Journal:  BMC Infect Dis       Date:  2015-11-09       Impact factor: 3.090

10.  A Cluster-Randomized Trial of Two Strategies to Improve Antibiotic Use for Patients with a Complicated Urinary Tract Infection.

Authors:  Veroniek Spoorenberg; Marlies E J L Hulscher; Ronald B Geskus; Theo M de Reijke; Brent C Opmeer; Jan M Prins; Suzanne E Geerlings
Journal:  PLoS One       Date:  2015-12-04       Impact factor: 3.240

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.